AngioDynamics (ANGO)

Executive Summary

AngioDynamics is a global medical device company specializing in minimally invasive technologies for vascular disease and cancer treatment. Founded in 1988 and headquartered in Latham, New York, the company offers a diversified portfolio including atherectomy, thrombectomy, and tumor ablation platforms. With a strong focus on interventional radiology, vascular surgery, and oncology, AngioDynamics aims to improve patient outcomes through innovative, less invasive solutions. The company's product lineup features the AlphaVac mechanical aspiration thrombectomy system and the NanoKnife irreversible electroporation system for tumor ablation, both of which address significant unmet needs in their respective markets. While the company faces competition from larger players, its niche focus and continuous product development provide a differentiated position. Financially, AngioDynamics has demonstrated resilience, with a valuation around $460 million, and benefits from recurring revenue from consumables. Recent strategic initiatives include expanding the AlphaVac indication and investing in next-generation ablation technologies. The company is well-positioned to capitalize on the growing preference for minimally invasive procedures, driven by an aging population and rising incidence of vascular and oncologic diseases. However, near-term headwinds include supply chain challenges and healthcare budget constraints. Overall, AngioDynamics presents a balanced risk-reward profile with moderate growth prospects.

Upcoming Catalysts (preview)

• Q2 2026FDA approval for expanded AlphaVac indication in pulmonary embolism70% success
• Q4 2026Launch of new generation NanoKnife system with improved targeting60% success
• Q1 2027Fiscal year 2026 earnings release with updated growth guidance90% success